Search Videos and More
San Antonio Breast Cancer Symposium (SABCS): December 2021Dana-Farber Cancer Institute faculty highlights from the 2021 San Antonio Breast Cancer Symposium.
Inadequate SARS-COV-2 Vaccine Effectiveness in Patients with Multiple Myeloma: A Large Nationwide Veterans Affairs StudyDana-Farber Cancer Institute's Nikhil C. Munshi, MD, details study looking at COVID-19 vaccine effectiveness in patients with multiple myeloma. Research presented at ASH21.
Blood Cancer Research: Clinical Trial Helps Younger PatientA patient shares her journey getting diagnosed with chronic lymphocytic leukemia in her 30's. Dana-Farber Cancer Institute's Matthew Davids, MD, MMSc, enrolled her on a clinical trial and details the results of that study. The research is now getting presented at ASH21.
ASH 2021 Highlights - CMERegister for 2021 ASH Highlights CME
New Study Reveals Elevated Rates of Blood Cancer Precursor Condition in Groups at High Risk for Multiple MyelomaDana-Farber Cancer Institute research shows elevated rates of a blood cancer precursor condition in groups at high risk for multiple myeloma.
American Society of Hematology (ASH) Annual MeetingAs leaders in blood and blood cancer research, physicians and scientists from Dana-Farber Cancer Institute shared advances and insights at the 63rd Annual Meeting of the American Society of Hematology (ASH) on December 11–14, 2021 in Atlanta, Georgia
New Study Reveals Elevated Rates of Blood Cancer Precursor Condition in Groups at High Risk for Multiple MyelomaThe first results from the largest screening study yet conducted in the United States of individuals at above-average risk for the blood cancer multiple myeloma have revealed higher rates of a myeloma precursor condition in older adults who are Black or who have a close family member with a current or past blood cancer.
Adjuvant Palbociclib in HR+/HER2 Early Breast Cancer - Final results from PALLAS TrialDana-Farber's Erica Mayer, MD, MPH discusses the final analysis of the International Phase 3 PALLAS clinical trial presented at the 2021 San Antonio Breast Cancer Symposium.
GS2-05 Update on the Combined TEXT and SOFT TrialsDana-Farber's Meredith Regan, ScD presented an update on the SOFT/TEXT clinical trials at the 2021 San Antonio Breast Cancer Symposium.
Dana-Farber Researchers Present Findings at San Antonio Breast Cancer SymposiumResearchers from Dana-Farber Cancer Institute will present more than 30 research studies at the 44th annual San Antonio Breast Cancer Symposium on December 7-10th.
ASH 2021 Featured Oral PresentationsThe Annual Meeting of the American Society of Hematology (ASH) will take place December 11-14th. To keep-up with latest advances, the live schedule of oral presentations by Dana-Farber faculty is attached for your convenience.
Dana-Farber at ASCOThe Annual Meeting of the American Society of Clinical Oncology (ASCO) will take place virtually June 4-8th.